|
FDA OKs Expanded Indication for Vascepa in Cardiovascular Risk Reduction
|
 Officials with the FDA have approved a new indication and label expansion for icosapent ethyl (Vascepa, Amarin), making it the first FDA-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment.
|
|
More
|
